Characterization of full-length CNBP expanded alleles in myotonic dystrophy type 2 patients by Cas9-mediated enrichment and nanopore sequencing

Abstract

Myotonic dystrophy type 2 (DM2) is caused by CCTG repeat expansions in the CNBP gene, comprising 75 to >11,000 units and featuring extensive mosaicism, making it challenging to sequence fully-expanded alleles. To overcome these limitations, we used PCR-free Cas9-mediated nanopore sequencing to characterize CNBP repeat expansions at the single-nucleotide level in nine DM2 patients. The length of normal and expanded alleles can be assessed precisely using this strategy, agreeing with traditional methods, and revealing the degree of mosaicism. We also sequenced an entire ~50 kbp expansion, which has not been achieved previously for DM2 or any other repeat-expansion disorders. Our approach precisely counted the repeats and identified the repeat pattern for both short interrupted and uninterrupted alleles. Interestingly, in the expanded alleles, only two DM2 samples featured the expected pure CCTG repeat pattern, while the other seven presented also TCTG blocks at the 3′ end, which have not been reported before in DM2 patients, but confirmed hereby with orthogonal methods. The demonstrated approach simultaneously determines repeat length, structure/motif and the extent of somatic mosaicism, promising to improve the molecular diagnosis of DM2 and achieve more accurate genotype-phenotype correlations for the better stratification of DM2 patients in clinical trials.

Data availability

The sequencing data generated in this study have been submitted to the NCBI BioProject database (https://www.ncbi.nlm.nih.gov/bioproject/) under accession number PRJNA818354. For revision purposes, reviewers can download data from the following link: https://dataview.ncbi.nlm.nih.gov/object/PRJNA818354?reviewer=1g4lp9ijkgv5s07is6imnot6ch

The following data sets were generated

Article and author information

Author details

  1. Massimiliano Alfano

    Department of Biotechnology, University of Verona, Verona, Italy
    Competing interests
    No competing interests declared.
  2. Luca De Antoni

    Department of Biotechnology, University of Verona, Verona, Italy
    Competing interests
    No competing interests declared.
  3. Federica Centofanti

    Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
    Competing interests
    No competing interests declared.
  4. Virginia Veronica Visconti

    Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
    Competing interests
    No competing interests declared.
  5. Simone Maestri

    Department of Biotechnology, University of Verona, Verona, Italy
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1192-0684
  6. Chiara Degli Esposti

    Department of Biotechnology, University of Verona, Verona, Italy
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5974-4915
  7. Roberto Massa

    Department of Systems Medicine (Neurology), University of Rome Tor Vergata, Rome, Italy
    Competing interests
    No competing interests declared.
  8. Maria Rosaria D'Apice

    Laboratory of Medical Genetics, University of Rome Tor Vergata, Rome, Italy
    Competing interests
    No competing interests declared.
  9. Giuseppe Novelli

    Laboratory of Medical Genetics, University of Rome Tor Vergata, Rome, Italy
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7781-602X
  10. Massimo Delledonne

    Department of Biotechnology, University of Verona, Verona, Italy
    Competing interests
    Massimo Delledonne, is a partner of Genartis srl.
  11. Annalisa Botta

    Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
    For correspondence
    botta@med.uniroma2.it
    Competing interests
    No competing interests declared.
  12. Marzia Rossato

    Department of Biotechnology, University of Verona, Verona, Italy
    For correspondence
    marzia.rossato@univr.it
    Competing interests
    Marzia Rossato, is a partner of Genartis srl, Verona.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6101-1550

Funding

Muscular Dystrophy Association (MDA 876149)

  • Massimo Delledonne

Italian DiMio onlus association (DM0000010)

  • Annalisa Botta

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The study was approved by the institutional review board of Policlinico Tor Vergata (document no. 232/19). All experimental procedures were carried out according to The Code of Ethics of the World Medical Association (Declaration of Helsinki). Informed consent was obtained from all nine participants and all samples and clinical information were anonymized immediately after collection using a unique alphanumeric identification code.

Copyright

© 2022, Alfano et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,027
    views
  • 361
    downloads
  • 17
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Massimiliano Alfano
  2. Luca De Antoni
  3. Federica Centofanti
  4. Virginia Veronica Visconti
  5. Simone Maestri
  6. Chiara Degli Esposti
  7. Roberto Massa
  8. Maria Rosaria D'Apice
  9. Giuseppe Novelli
  10. Massimo Delledonne
  11. Annalisa Botta
  12. Marzia Rossato
(2022)
Characterization of full-length CNBP expanded alleles in myotonic dystrophy type 2 patients by Cas9-mediated enrichment and nanopore sequencing
eLife 11:e80229.
https://doi.org/10.7554/eLife.80229

Share this article

https://doi.org/10.7554/eLife.80229

Further reading

    1. Chromosomes and Gene Expression
    2. Genetics and Genomics
    Hans Tobias Gustafsson, Lucas Ferguson ... Oliver J Rando
    Research Article

    Among the major classes of RNAs in the cell, tRNAs remain the most difficult to characterize via deep sequencing approaches, as tRNA structure and nucleotide modifications can each interfere with cDNA synthesis by commonly-used reverse transcriptases (RTs). Here, we benchmark a recently-developed RNA cloning protocol, termed Ordered Two-Template Relay (OTTR), to characterize intact tRNAs and tRNA fragments in budding yeast and in mouse tissues. We show that OTTR successfully captures both full-length tRNAs and tRNA fragments in budding yeast and in mouse reproductive tissues without any prior enzymatic treatment, and that tRNA cloning efficiency can be further enhanced via AlkB-mediated demethylation of modified nucleotides. As with other recent tRNA cloning protocols, we find that a subset of nucleotide modifications leave misincorporation signatures in OTTR datasets, enabling their detection without any additional protocol steps. Focusing on tRNA cleavage products, we compare OTTR with several standard small RNA-Seq protocols, finding that OTTR provides the most accurate picture of tRNA fragment levels by comparison to "ground truth" Northern blots. Applying this protocol to mature mouse spermatozoa, our data dramatically alter our understanding of the small RNA cargo of mature mammalian sperm, revealing a far more complex population of tRNA fragments - including both 5′ and 3′ tRNA halves derived from the majority of tRNAs – than previously appreciated. Taken together, our data confirm the superior performance of OTTR to commercial protocols in analysis of tRNA fragments, and force a reappraisal of potential epigenetic functions of the sperm small RNA payload.

    1. Cell Biology
    2. Genetics and Genomics
    Keva Li, Nicholas Tolman ... UK Biobank Eye and Vision Consortium
    Research Article

    A glaucoma polygenic risk score (PRS) can effectively identify disease risk, but some individuals with high PRS do not develop glaucoma. Factors contributing to this resilience remain unclear. Using 4,658 glaucoma cases and 113,040 controls in a cross-sectional study of the UK Biobank, we investigated whether plasma metabolites enhanced glaucoma prediction and if a metabolomic signature of resilience in high-genetic-risk individuals existed. Logistic regression models incorporating 168 NMR-based metabolites into PRS-based glaucoma assessments were developed, with multiple comparison corrections applied. While metabolites weakly predicted glaucoma (Area Under the Curve = 0.579), they offered marginal prediction improvement in PRS-only-based models (p=0.004). We identified a metabolomic signature associated with resilience in the top glaucoma PRS decile, with elevated glycolysis-related metabolites—lactate (p=8.8E-12), pyruvate (p=1.9E-10), and citrate (p=0.02)—linked to reduced glaucoma prevalence. These metabolites combined significantly modified the PRS-glaucoma relationship (Pinteraction = 0.011). Higher total resilience metabolite levels within the highest PRS quartile corresponded to lower glaucoma prevalence (Odds Ratiohighest vs. lowest total resilience metabolite quartile=0.71, 95% Confidence Interval = 0.64–0.80). As pyruvate is a foundational metabolite linking glycolysis to tricarboxylic acid cycle metabolism and ATP generation, we pursued experimental validation for this putative resilience biomarker in a human-relevant Mus musculus glaucoma model. Dietary pyruvate mitigated elevated intraocular pressure (p=0.002) and optic nerve damage (p<0.0003) in Lmx1bV265D mice. These findings highlight the protective role of pyruvate-related metabolism against glaucoma and suggest potential avenues for therapeutic intervention.